• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Novanta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    6/9/26 5:00:16 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous
    Get the next $NOVT alert in real time by email
    8-K
    false000107693000010769302026-06-082026-06-080001076930us-gaap:CommonStockMember2026-06-082026-06-080001076930novt:SixPointFiveZeroPercentTangibleEquityUnitsMember2026-06-082026-06-08

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 8, 2026

    NOVANTA INC.

    (Exact name of registrant as specified in is charter)

     

    New Brunswick, Canada

    001-35083

    98-0110412

    (State or other jurisdiction

    of incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

     

     

     

    125 Middlesex Turnpike

    Bedford, Massachusetts

    01730

    (Address of principal executive offices)

    (Zip Code)

    Registrant’s telephone number, including area code: (781) 266-5700

    Not Applicable

    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

    Common shares, no par value

     

    NOVT

     

    Nasdaq Global Select Market

    6.50% Tangible Equity Units

     

    NOVTU

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


     

    Item 1.01 Entry into a Material Definitive Agreement.

    On June 8, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and other accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). The closing of the Private Placement (the “Closing”) is expected to occur on June 11, 2026, subject to the satisfaction of customary closing conditions.

    Pursuant to the Purchase Agreement, the Purchasers agreed to purchase an aggregate of 2,142,857 common shares, no par value, of the Company (the “Common Shares”), at a purchase price per share of $140.00, for an aggregate purchase price of approximately $300.0 million. Based on 35,613,303 Common Shares outstanding as of June 8, 2026, and an additional 4,717,185 Common Shares that represent the minimum number of Common Shares issuable upon the settlement of the share purchase contracts relating to the Company’s outstanding Tangible Equity Units as of June 8, 2026, assuming the consummation of the Private Placement, there would be an aggregate of 42,473,345 Common Shares outstanding or issuable upon the minimum settlement of the share purchase contracts relating to outstanding Tangible Equity Units following the Closing.

    The Purchase Agreement contains customary representations and warranties of the Company, on the one hand, and the Purchasers, on the other hand, and customary conditions to closing.

    Also on June 8, 2026, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers, which provides that the Company will register the resale of the Common Shares sold by the Company in the Private Placement. The Company is required to prepare and file a registration statement with the Securities and Exchange Commission no later than 30 days after the date of the Closing, and to use its reasonable best efforts to have the registration statement declared effective within 45 days thereafter, subject to certain exceptions. If the Company is a well-known seasoned issuer (as defined in Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”)) and an existing registration statement of the Company on Form S-3ASR is effective, the Company may instead elect to file a prospectus supplement to such existing registration statement registering the resale of the Common Shares sold by the Company in the Private Placement in lieu of filing a new registration statement.

    The Company has also agreed to, among other things, indemnify the Purchasers, their officers, directors, agents, partners, members, managers, stockholders, affiliates, investment advisers, employees and other control persons under the registration statement from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to the Company’s obligations under the Registration Rights Agreement.

    The Common Shares issued and sold to the Purchasers under the Purchase Agreement will not be registered under the Securities Act in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, or under any state securities laws. The Company relied on this exemption from registration based in part on representations made by the Purchasers. The Common Shares may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. Neither this Current Report on Form 8-K, nor the exhibits attached hereto, is an offer to sell or the solicitation of an offer to buy the securities described herein.

    The Company engaged J.P. Morgan Securities LLC, William Blair & Company, L.L.C., CJS Securities, Inc. and PNC Capital Markets LLC as placement agents for the Private Placement. The Company has agreed to pay customary placement agent and other financial advisory fees and, under certain circumstances, reimburse certain expenses of the placement agents.

    The foregoing summary of the Purchase Agreement and the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement and the Registration Rights Agreement, copies of which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K, respectively, and are incorporated by reference herein.

    Item 3.02 Unregistered Sales of Equity Securities

    The information contained in Item 1.01 01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.

    Item 8.01 Other Events.

    On June 9, 2026, the Company issued a press release announcing the pricing of the Private Placement described in Item 1.01 of this Current Report on Form 8-K. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     


     

    Cautionary Note Regarding Forward Looking Statements

    This Current Report on Form 8-K contains forward-looking statements that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to various risks and uncertainties and include all statements that are not historical statements of fact and those regarding the Company’s intent, belief or expectations. Forward-looking statements are generally identifiable by use of forward-looking terminology such as “may,” “will,” “could,” “potential,” “intend,” “expect,” “estimate,” “believe,” “plan,” or other similar words or expressions, and include statements regarding the closing of the Private Placement, the Company’s agreement to register the Common Shares sold in the Private Placement and the expected amount of proceeds from the Private Placement. These forward-looking statements are based on certain assumptions and expectations, and the Company’s ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Although the Company believes that expectations reflected in any forward-looking statements are based on reasonable assumptions, it can give no assurance that its assumptions or expectations will be attained and actual results and performance could differ materially from those projected. Factors which could have a material adverse effect on the Company’s operations and future prospects or which could cause events or circumstances to differ from the forward-looking statements include, but are not limited to, the risks detailed from time to time in the Company’s filings with the SEC, including those set forth in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements in such SEC filings. Readers are cautioned not to place undue reliance on any of these forward-looking statements, which reflect management’s views as of the date of this Current Report. The Company cannot guarantee future results, levels of activity, performance or achievements, and, except as required by law, it expressly disclaims any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations with regard thereto or change in events, conditions or circumstances on which any statement is based.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    Number

    Description

     10.1†#

    Form of Securities Purchase Agreement, dated June 8, 2026, by and between Novanta Inc. and each purchaser thereto.

     10.2

     

    Form of Registration Rights Agreement, dated June 8, 2026, by and between Novanta Inc. and the other parties thereto.

     99.1

    Press Release, dated June 9, 2026

     104

     

     The cover page from the Company’s Current Report on Form 8-K formatted in Inline XBRL.

     

    †

    Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the Securities and Exchange Commission; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.

     

    #

    The representations and warranties contained in this agreement were made only for purposes of the transactions contemplated by the agreement as of specific dates and may have been qualified by certain disclosures between the parties and a contractual standard of materiality different from those generally applicable under securities laws, among other limitations. The representations and warranties were made for purposes of allocating contractual risk between the parties to the agreement and should not be relied upon as a disclosure of factual information relating to the Company, the Purchasers or the transactions described in this Current Report on Form 8-K.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Novanta Inc.

    Date: June 9, 2026

    By:

    /s/ Robert J. Buckley

    Robert J. Buckley

    Chief Financial Officer

     

     

     


    Get the next $NOVT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NOVT

    DatePrice TargetRatingAnalyst
    3/30/2026$144.00Neutral → Outperform
    Robert W. Baird
    5/11/2022Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $NOVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Novanta upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Novanta from Neutral to Outperform and set a new price target of $144.00

    3/30/26 8:13:23 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta upgraded by William Blair

    William Blair upgraded Novanta from Mkt Perform to Outperform

    5/11/22 6:19:56 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Glastra Matthijs sold $1,096,273 worth of shares (6,500 units at $168.66) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 36,261 units (SEC Form 4)

    4 - NOVANTA INC (0001076930) (Issuer)

    6/4/26 4:05:16 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Chief Executive Officer Glastra Matthijs sold $1,128,244 worth of shares (7,500 units at $150.43) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 42,761 units (SEC Form 4)

    4 - NOVANTA INC (0001076930) (Issuer)

    5/14/26 4:06:13 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Chief Executive Officer Glastra Matthijs sold $852,348 worth of shares (6,500 units at $131.13) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 50,261 units (SEC Form 4)

    4 - NOVANTA INC (0001076930) (Issuer)

    5/7/26 4:16:16 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    SEC Filings

    View All

    Novanta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - NOVANTA INC (0001076930) (Filer)

    6/9/26 5:00:16 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NOVANTA INC (0001076930) (Filer)

    6/9/26 6:02:06 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - NOVANTA INC (0001076930) (Filer)

    5/29/26 4:45:15 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Novanta Inc.

    SC 13G/A - NOVANTA INC (0001076930) (Subject)

    11/14/24 1:22:36 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G filed by Novanta Inc.

    SC 13G - NOVANTA INC (0001076930) (Subject)

    2/14/24 10:02:59 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G/A filed by Novanta Inc. (Amendment)

    SC 13G/A - NOVANTA INC (0001076930) (Subject)

    2/13/24 5:09:44 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novanta to Present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026

    Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and Chuck Ravetto, Chief Operating Officer, are scheduled to present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026, in White Plains, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation

    6/22/26 5:00:00 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. Announces $300 Million Private Placement

    Novanta Inc. ("Novanta" or the "Company") announced today that it has entered into a securities purchase agreement for a private placement of the Company's common shares ("Common Shares") to institutional and other accredited investors that is expected to result in gross proceeds of approximately $300 million to the Company, before placement agent fees and offering expenses. Pursuant to the terms of the securities purchase agreement, the investors agreed to purchase an aggregate of 2,142,857 Common Shares at a purchase price of $140.00 per share. The private placement is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions. The offer and s

    6/9/26 6:15:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. Announces Acquisition of Riverpoint Medical

    Accelerates Novanta's strategic direction, expands portfolio into high-growth minimally invasive surgery segment, and doubles recurring medical consumables revenue Transaction is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical ("Riverpoint Medical" or "Riverpoint"), a category leader in high-growth minimally invasive surgical consumables, from

    6/9/26 6:00:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Financials

    Live finance-specific insights

    View All

    Novanta Inc. Announces Acquisition of Riverpoint Medical

    Accelerates Novanta's strategic direction, expands portfolio into high-growth minimally invasive surgery segment, and doubles recurring medical consumables revenue Transaction is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical ("Riverpoint Medical" or "Riverpoint"), a category leader in high-growth minimally invasive surgical consumables, from

    6/9/26 6:00:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Announces Financial Results for the First Quarter 2026

    First Quarter 2026 GAAP Revenue increased 10% to $258 million First Quarter 2026 GAAP Net Income was $21 million, and Adjusted EBITDA increased 14% to $57 million First Quarter 2026 GAAP Diluted EPS was $0.51, and Adjusted Diluted EPS increased 9% to $0.81 Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2026. Financial Highlights Three Months Ended   (In millions, except per share amounts) April 3,     March 28,     2026     2025  

    5/11/26 4:45:00 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. Announces Schedule of First Quarter 2026 Earnings Release and Conference Call

    Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2026 results after the close of U.S. financial markets on Monday, May 11, 2026. The Company will host a conference call on Tuesday, May 12, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hou

    4/14/26 11:00:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Leadership Updates

    Live Leadership Updates

    View All

    IDEX Corporation Appoints Stephanie Disher and Matthijs Glastra to Board of Directors; David Parry and Livingston Satterthwaite to Retire

    IDEX Corporation (NYSE:IEX) today announced the appointment of Stephanie ("Steph") Disher and Matthijs Glastra to the company's Board of Directors. The appointments, effective Friday, February 21, 2025, increase the size of the Board from 10 to 12 directors. Ms. Disher will serve on the Board's Nominating and Corporate Governance Committee, and Mr. Glastra will serve on the Board's Audit Committee. Ms. Disher currently serves as Chief Executive Officer of Atmus Filtration Technologies Inc. (NYSE:ATMU), a leader in filtration and media solutions. She has extensive global leadership experience in finance and operations from her time at Atmus, Cummins Inc. and BP, p.l.c. Mr. Glastra currentl

    2/20/25 5:07:00 PM ET
    $ATMU
    $IEX
    $NOVT
    Auto Parts:O.E.M.
    Consumer Discretionary
    Fluid Controls
    Industrials

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care